30 Oct Date October 30, 2024 Categories Medregen Phase II ARDS IND Submission China (NMPA) In our effort to launch an international phase II trial in ARDS (NCT06308926), Medregen has also successfully submitted an IND for...
14 Sep Date September 14, 2024 Categories Medregen Phase II Wound Healing Study Completed Northwestern University has completed recruitment and follow-up of all 10 subjects in the study. The database is expected to be cl...
03 May Date May 3, 2024 Categories Medregen FDA Phase II IND Approval (ARDS) Medregen is excited to announce that the FDA has approved our IND to initiate a phase IIa, dose-ranging study (NCT06308926) in Acu...